Malignant Exocrine Pancreatic Neoplasm
NCI Definition: A malignant neoplasm that arises from the epithelial cells of the exocrine pancreatic tissue. 
Malignant exocrine pancreatic neoplasms most frequently harbor alterations in KRAS, TP53, CDKN2A, SMAD4, and CDKN2B .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in malignant exocrine pancreatic neoplasm .
There is 1 clinical trial for malignant exocrine pancreatic neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant exocrine pancreatic neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
Sgn-stnv is the most common intervention in malignant exocrine pancreatic neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.